Calliditas Therapeutics AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was SEK 198.17 million. Net income was SEK 10.84 million compared to net loss of SEK 138.02 million a year ago. Basic earnings per share from continuing operations was SEK 0.21 compared to basic loss per share from continuing operations of SEK 2.77 a year ago. Diluted earnings per share from continuing operations was SEK 0.21 compared to diluted loss per share from continuing operations of SEK 2.77 a year ago. For the nine months, sales was SEK 198.17 million compared to SEK 0.474 million a year ago. Net loss was SEK 274.46 million compared to SEK 263.06 million a year ago. Basic loss per share from continuing operations was SEK 5.45 compared to SEK 6.09 a year ago. Diluted loss per share from continuing operations was SEK 5.45 compared to SEK 6.09 a year ago.